We have been receiving questions regarding Afstyla and whether WAPPS-Hemo already multiplies the resultant measurements by a factor of 2 if a one-stage clotting assay was used. Conversely, the scientific community recommends the use of chromogenic assays or to “calibrate” the clotting assays with a specific standard.
We are excited to announce that as of today, myWAPPS, a patient tool based on WAPPS-Hemo, is globally available from the App store and Google Play.
Due to the different labelled potencies of Xyntha and ReFacto AF (1 IU: 1.38 IU), please ensure that you have selected the correct concentrate that your patient has infused with (Xyntha vs. ReFacto AF). WAPPS-Hemo will take into account potency conversion and you do not need to make any adjustments to your measurements.
With the recent availability for WAPPS-Hemo to process Rebinyn/Refixia requests, we recognize that there are recommendations to use certain lab test assays over others. Based on studies by Bowyer et al 2016, ABC et al 2015, … we recommend that FIX:C in Rebinyn/Refixia-containing plasma samples can be most accurately measured with one-stage clotting assays using SynthAFax or DG Synth [to be internally verified], whereas there is no preference with chromogenic assays.
At WAPPS-News we post the latest updates and changes to the WAPPS-Hemo program. Check back with us regularly. Contact us if you have any questions.
The WAPPS-HEMO Team
If you have any WAPPS-Hemo related research or news items you would like to share, please contact us
© 2024 Copyright WAPPS-Hemo